Friday the 13th has turned into a horror story for Australian biotech Immutep, whose share price collapsed after it abandoned a pivotal trial of its lead drug. Immutep's ASX-listed stock fell more ...
Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients with ...
Explore the staff augmentation market in Southeast Asia and discover what Singapore businesses need to know about talent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results